“If they give me a vaccine, I’ll do anything” … The United States and pharmaceutical companies negotiate additional large-scale purchases

Entry 2020.12.17 10:28

“The US government invests billions in large pharmaceutical companies, tempts priority supply”

The US government is reported to be conducting additional negotiations with Pfizer in preparation for a large-scale supply shortage called the “vaccine cliff.” The US government, which previously rejected Pfizer’s offer of additional purchases, is trying to secure large-scale actions by offering various grants to Pfizer while facing criticism from politicians and public opinion.

According to the Washington Post (WP) on the 16th (local time), the Trump administration is negotiating with Pfizer to secure more Corona 19 vaccines for the general public this spring. According to the WP, Health and Welfare Minister Alex Aza is working to purchase additional vaccines from Pfizer for the second quarter of next year.

Previously, according to major foreign outlets such as The New York Times, the Trump administration was criticized for rejecting the opportunity to nearly double the amount of Pfizer vaccine purchases in October. Negotiations failed due to disagreements over vaccine prices and delivery dates. Later, when the facts became known, the Trump administration was criticized for responding passively to the demand for vaccines.

Although the US government belatedly initiated additional purchases, Pfizer is also in a difficult position to promise a smooth supply. This is because, in the face of raw material shortages, large-scale vaccine purchase requests are being made not only in the United States, but also in Europe, Asia, Africa and South America. Consequently, the US government is offering various assistance to Pfizer and is negotiating the purchase of as many vaccines as possible.

Meanwhile, according to the New York Times (NYT), the US is putting pressure on the speed and volume of these vaccine companies, spending billions of dollars to support research, development and manufacturing of five vaccines. promising, including Pfizer. Of course, the condition of support is that it must take precedence over access to production volumes.

According to NYT, the US has secured 100 million lots as an option to purchase an additional 500 million lots from Pfizer, and plans to add 300 million lots after securing 200 million lots in Modena. Additionally, he has booked 81,000 episodes of AstraZeneca-Oxford University, Johnson & Johnson, Nova Bax, Sanofi-Glaxos Miss Kline.